A retrospective descriptive study was conducted in patients with MDR-TB in CAT, Cocody and Treichville Pneumo-Physiology Departments, from November 2013 to December 2015. Sputum from included patients was cultured monthly for 9 months. Out of 132 patients put on a short 9-month regimen, 22 (16.66%) were HIV infected including 6 cases of relapse and 4 lost to follow-up. At the consolidation phase of the short course of MDR-TB, cultures were negative for 14/18 (77.77%) and positive for 4/18 (22.22%). The D516V mutation in the rpoB gene was the most frequent among cured patients with 42.85%. One failure was observed in a patient infected with a double mutated strain (L511P, S522T). Among the failures, 2 patients were XDR. The estimated Od ratio according to rpoB gene mutation type and clinical category was 0.81 95% CI [0.13 ;20.57] and 0.27 95% CI [0.002 ; 2.82], respectively. The type of rpoB mutation and clinical category did not influence the treatment outcome of HIV/TBMR co-infected patients.